ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Groups Urge Passage of Health Care Reform Legislation

January 29, 2010

In Brief: Baltimore Resigns as Rockefeller President; Perry Named Medical Director At Ellis Fischel

December 13, 1991

In Brief: Christopher Walsh Named Dana-Farber President; Sachs Leaves NCI; Acoustic Neuroma Conference

August 16, 1991

Full Text Of Saffiotti’s Statement

May 7, 1976

Seventeen New ACS-Roosevelt Grants Awarded

July 25, 1975

Insurer Declines To Cover Avastin For Breast Cancer, Institutes Review Procedure For Exceptional Cases

October 21, 2011